Oral adverse effects due to the use of nevirapine

Journal of Contemporary Dental Practice

Volumn 9, Issue 1, 2008, Pages 084-090

  Moura, Mariela Dutra Gontijo ^a   Senna, Maria Inês Barreiros ^a   Madureira, Davidson Fróis ^b   Fonseca, Linaena Méricy Silva ^c   Mesquita, Ricardo Alves ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b and Oral Pathology

^c Orestes Diniz's Treatment Center of Parasitic and Infectious Diseases   (Brazil)

Author keywords

Adverse effects; Antiretroviral; HAART; HIV infection; Nevirapine; NNRTI

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NEVIRAPINE;

ADULT; ARTICLE; BLOOD; BURNING MOUTH SYNDROME; CASE REPORT; CD4 LYMPHOCYTE COUNT; CHEMICALLY INDUCED DISORDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOUTH DISEASE; RASH; TASTE DISORDER; VIRUS LOAD; XEROSTOMIA;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BURNING MOUTH SYNDROME; CD4 LYMPHOCYTE COUNT; EXANTHEMA; HIV INFECTIONS; HUMANS; MALE; MOUTH DISEASES; NEVIRAPINE; TASTE DISORDERS; VIRAL LOAD; XEROSTOMIA;

EID: 38049170672     PISSN: None     EISSN: 15263711     Source Type: Journal    
DOI: 10.5005/jcdp-9-1-84     Document Type: Article

References (20)

1. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356 (9239):1423-30.
2. Ena J, Pasquau F. Once-a-day highly active antiretroviral therapy: a systematic review. Clin Infect Dis. 2003; 36(9):1186-90.
3. Hashimoto H, Kapiga SH, Murata Y. Mass treatment with nevirapine to prevent mother-to-child transmission of HIV/AIDS in sub-Saharan African countries. J Obstet Gynaecol Res. 2002; 28(6):313-9.
4. Patton LL, McKaig R, Strauss R, Rogers D, Eron JJ Jr. Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000; 89(3):299-304.
5. Pirmohamed M, Park BK. HIV and drug allergy. Curr Opin Allergy Clin Immunol. 2001; 1(4):311-6.
6. Schmidt-Westhausen AM, Priepke F, Bergmann FJ, Reichart PA. Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy. J Oral Pathol Med. 2000; 29(7):336-41.
7. Scully C, Dios PD. Orofacial effects of antiretroviral therapies. Oral Dis. 2001; 7(4):205-10.
8. Tappuni AR, Fleming GJP. The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: a UK study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001; 92(6):623-8.
9. Cherry-Peppers G, Daniels CO, Meeks V, Sanders CF, Reznik D. Oral manifestations in the era of HAART. J Natl Med Assoc. 2003; 95(2 Suppl 2):21S-32S.
10. Depaola LG. Human immunodeficiency virus disease: natural history and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000; 90(3):266-70.
11. Krogstad P, Lee S, Johnson G, Stanley K, McNamara J, Moye J, Jackson JB, Aguayo R, Dieudonne A, Khoury M, Mendez H, Nachman S, Wiznia A. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clin Infect Dis. 2002; 34(7):991-1001.
12. Wetterwald E, Le Cleach I, Michael C, David E, Revuz J. Nevirapine-induced overlap stevens-johnson syndrome/toxic epidermal necrolysis. Br J Dermatol. 1999; 140(5):980-2.
13. Montessori V, Press N, Harris M, Akagi A, Montaner JSG. Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004; 170(2):229-38.
14. Bersoff-Matcha SJ, Miller WC, Aberg JA, Van Der Horst C, Hamrick Jr HJ, Powderly WG, Mundy LM. Sex differences in nevirapine rash. Clin Infect Dis. 2001; 32(1):124-9.
15. Montaner JS, Cahn P, Zala C, Cassseti LI, Losso M, Hall DB, Wruck J, McDonough M, Gigliotti M, Robinson PA. Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. J Acquir Immune Defic Syndr. 2003; 33(1):41-6.
16. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther. 1998; 20(6):1071-92.
17. Knobel H, Miro JM, Domingo P, Rivero A, Marquez M, Force L, Gonzalez A, De Miguel V, Sanz J, Boix V, Blanco JL, Locutura J. Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 study. J Acquir Immune Defic Syndr. 2001; 28(1):14-8.
18. Bonnet F, Lawson-Ayayi, Thiébaut R, Ramanampamonjy R, Lacoste D, Bernard N, Malvy D, Bonarek M, Djossou F, Beylot J, Dabis F, Morlat P. A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999. Clin Infect Dis. 2002; 35(10):1231-7.
19. Ficarra G, Flaitz CM, Gaglioti D, Piluso S, Milo D, Adler-Storthz K, Eversole LR. White lichenoid lesions of the buccal mucosa in patients with HIV infection. Oral Surg Oral Med Oral Pathol. 1993; 76(4):460-6.
20. Carder KR. Hypersensitivity reactions in neonates and infants. Dermatol Ther. 2005; 18(2):160-75.